Background. Cyclosporine A (CsA) is associated with negative side effects such as endothelial injury, which may lead to transplant vasculopathy. CsA can impair nitric oxide (NO) homeostasis. Therefore, tetrahydrobiopterin (BH 4 ), a NO synthase cofactor, may limit endothelial injury by improving NO production. Our study examines the effect of CsA and BH 4 exposure on endothelial function. Methods. Lewis rats were injected with CsA, BH 4 , CsAϩBH 4 , or saline intraperitoneally daily for 2 weeks. With use of a small vessel myograph, thoracic aortic segments were assessed for endothelial-dependent (Edep) and independent relaxation after exposure to acetylcholine and sodium nitroprusside. Sensitivity to vasospasm was evaluated after exposure to endothelin (ET)-1. Results. CsA exposure resulted in impaired Edep vasorelaxation compared with control (Pϭ0.01). BH 4 attenuated the deleterious effects of CsA. Compared with control, all treatment groups demonstrated significantly increased sensitivity to ET-1. Furthermore, endothelial nitric oxide synthase expression in the thoracic aorta was reduced after CsA treatment, and this reduction was attenuated by BH 4 therapy (PϽ0.01). ET A receptor expression in the aorta was increased after CsA treatment, but BH 4 treatment prevented CsA-induced ET A over-expression (Pϭ0.004). However, ET B receptor expression was increased by BH 4 treatment compared with CsA and control (Pϭ0.02). Conclusion. Our findings suggest that CsA-induced vasomotor dysfunction is a result of alterations in both NO and ET-1 regulation and that BH 4 may prevent the deleterious effects of CsA. However, the beneficial effects of BH 4 are associated with increased sensitivity to ET-1. Therefore, a combination of BH 4 and ET-1 blockade may prove to be an ideal combination for preservation of endothelial function.
C yclosporine (CsA) is considered the cornerstone of immunosuppressive therapy and has significantly improved the results of clinical organ transplantation. CsA prolongs graft survival by reducing the incidence of acute rejection; however, CsA is associated with many negative side effects (1) (2) (3) . The side effects include nephrotoxicity, hepatotoxicity, neurotoxicity, and hypertension (1-3). More recently, endothelial dysfunction and the development of transplant vasculopathy (TxV) have been associated with the use of CsA (3) (4) (5) (6) (7) (8) (9) (10) . Potential etiologies for CsA-induced TxV are increases in plasma lipid concentrations, hypertension, or by direct injury to the endothelium (6, (11) (12) (13) . CsA-induced endothelial injury may result in impaired vascular homeostasis and TxV.
The pathophysiologic processes behind CsA-induced endothelial dysfunction are not fully elucidated. There is evidence that CsA results in impaired vasodilation (14 -16) and increases vasospasm (17) (18) (19) . Increased vasospasm may be caused by an increased release of vasoconstrictors or increased sensitivity to these vasoconstrictors. One such vasoconstrictor is endothelin (ET)-1. The plasma level of ET-1 after CsA treatment remains controversial, although most investigators have reported an increase in ET-1 levels after CsA treatment (14, 19 -26) . Altered nitric oxide (NO) homeostasis may result in impaired vasodilatory response (14) . Several investigators have demonstrated that CsA results in impaired NO production and increased production of free radicals, resulting in endothelial dysfunction (8, 14, (27) (28) .
NO is produced by the enzyme nitric oxide synthase (NOS) by converting L-arginine to L-citrulline and NO. NOS produces NO exclusively in its dimeric form. When in monomeric form, NOS produces the free radicals superoxide and peroxynitrite. NOS requires the cofactor tetrahydrobiopterin (BH 4 ) for dimerization and for efficient electron transport through the NOS complex (29 -31) . Therefore, deficiency of BH 4 can lead to free radical production and endothelial injury. BH 4 has been demonstrated to improve endothelial dysfunction in different animal and clinical situations (32) (33) (34) (35) (36) (37) .
We therefore hypothesized that CsA results in endothelial dysfunction by impaired NO and ET-1 homeostasis. We also hypothesized that BH 4 therapy may prevent CsA-induced endothelial dysfunction by improving NO production and limiting free radical injury. vised 1996). Male Lewis rats (200 -300 g) were administered the drug of interest (nϭ16 per group): saline control, CsA (5 mg/kg per day, normal clinical dose), BH 4 (7.5 mg/day, a dose demonstrated to preserve endothelial function in our preliminary studies), or CsAϩBH 4 by way of peritoneal injection for a period of 2 weeks before assessment of endothelial function. On the day of sacrifice, rats were anaesthetized using isoflurane. Median sternotomy was then performed and the heart excised for myocardial analysis and segments of aorta procured for assessment of endothelial function. Before heart excision, 1 mL 3 of blood from the right ventricle was collected for analysis of ET-1 plasma levels. The rats were then exsanguinated under general anesthesia.
Endothelial Function Assessment
Endothelial-dependent and independent vascular relaxation was assessed in isolated segments of thoracic aorta after treatment. The thoracic aorta was dissected, and arterial segments (5 mm in length) were used for the assessment of vascular function using a small vessel myograft for isometric tension recording. Vessels were then mounted on a pressure transducer, and maximum vasoconstriction was achieved with exposure to phenylephrine. After stabilization, endothelial-dependent relaxation was assessed by exposure to incremental increases in acetylcholine (Ach) concentration. Endothelial-independent relaxation was assessed by incremental exposure to sodium nitroprusside (SNP). The maximum relaxation from phenylephrine-induced vasoconstriction (Emax%) was compared between groups. ED 50 , calculated as the concentration required to achieve half-maximal vasorelaxation, was compared between groups. Sensitivity to vasospasm was assessed in vessels after stabilization after SNP washout. Incremental exposure to ET-1 was performed and Cmax% (percent maximum contraction) calculated as the maximum increase in tension from baseline. Each animal yielded two aortic segments. Data were included if the variability between segments was less than 10%, and data were averaged to yield one result per animal.
Assessment of Oxidative Injury
Assessments of 8-isoprostane levels were performed as an indicator of free-radical-mediated injury (38) . This stable end product of arachidonic acid oxidation is generated by reactive oxygen species injury (39) . Determination of 8-isoprostane levels in left ventricular (LV) myocardial tissue was performed using a commercially available kit (Cayman Chemical Company, Ann Arbor, MI). The percentage from baseline (LV from animals that received no intraperitoneal injections) was calculated to compare differences between groups.
Plasma Measurements
Right ventricular blood aspirated before exsanguination was used for analysis. Blood samples were then centrifuged (14,000 rpm) and the plasma fractions collected and snap frozen in liquid nitrogen. With use of C 18 Sep-Pack columns, plasma ET-1 was extracted after acidification with 1% trifluoroacetic acid. Plasma ET-1 levels were measured using a commercial ELISA assay (Biomedica, Vienna, Austria).
Western Blot Analysis
LV biopsies and thoracic aortas were collected immediately after harvesting. Biopsy specimens were then snap frozen in liquid nitrogen and stored at Ϫ80°C until analyzed. Biopsies were homogenized at 4°C and prepared for analysis. The protein concentration was determined by the method described by Bradford (40) .
Western immunoblotting was performed using chemiluminescence detection. The protein expression of inducible NOS (iNOS), endothelial NOS (eNOS), tumor necrosis factor (TNF)-␣, and transforming growth factor (TGF)-␤ was determined with the use of protein-specific monoclonal antibodies (Biosciences, Mississauga, Canada). ET A and ET B receptor (Rc) expression was measured with appropriate polyclonal antibodies (Chemicon, Temecula, CA). Samples were separated using 4% stacking and 10% running tris-glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Gels were then transferred to polyvinylidene fluoride membranes. Blocking was performed for 1 hour at room temperature using blocking buffer. Monoclonal immunoglobulin G at a dilution of 1:2,500 was reacted with the blots for 12 hours at 4°C. The blots were then incubated with secondary antibody for 1 hour after washing. Comparisons between groups were performed using densitometric analysis.
Statistical Analysis
Statistical analysis was performed with the SAS statistical software program Version 8.0 for Windows (SAS institute, Inc., Cary, NC). Continuous data were analyzed by analysis of variance and are expressed as the meanϮstandard deviation.
RESULTS
All animals survived until day of sacrifice with no complications. There was minimal variability from aortic segments within each animal, and no animals were excluded from the study.
Endothelial Function
CsA treatment impairs endothelial-dependent vasorelaxation of the thoracic aortic rings compared with control (Fig. 1A) . CsA resulted in an Emax% of 33Ϯ2% that was significantly lower than that of control 46Ϯ1% (Pϭ0.01). BH 4 therapy for CsA-treated animals normalized endothelial-dependent vasodilation to Ach (Fig. 1A) . Assessment of endothelial-independent vasorelaxation to SNP revealed no significant differences (Pϭ0.7) between groups (Fig. 1B) . However, when examining the concentration of SNP necessary to achieve 50% of maximal vasodilatory response, significant differences were seen between groups. CsA-(ED 50 3.2ϫ10 Ϫ8 Ϯ0.2 mole/L) treated animals required approximately double the concentration of SNP compared with control (ED 50 1.6ϫ10 Ϫ8 Ϯ0.1 mole/L) (Pϭ0.01). Furthermore, BH 4 treatment for CsA-treated animals (ED 50 2.0ϫ10 Ϫ8 Ϯ0.3 mole/L) prevented the increased ED 50 for SNP. BH 4 treatment alone (ED 50 1.0ϫ10 Ϫ8 Ϯ0.1 mole/L) resulted in a significantly lower ED 50 than that of control animals.
Significant differences were also found in vessel sensitivity to ET-1 exposure. Compared with control, all treatment groups demonstrated significantly increased sensitivity to ET-1 (Cmax: CsA, 256%Ϯ9%; BH 4 , 242%Ϯ8%; CsAϩBH 4 , 268%Ϯ4%; control, 210%Ϯ5%, Pϭ0.03) (Fig. 2) .
Plasma ET-1 Levels
Plasma ET-1 levels were not significantly different between control and CsA-treated animals (Fig. 3) . However, BH 4 and CsAϩBH 4 treatment resulted in a 50% reduction of ET-1 levels compared with both control and CsA-treated animals (PϽ0.01). Control animals had an ET-1 plasma concentration of 1.2Ϯ0.4 fmol/L, which is in the reported normal range (20) .
Endothelin Receptor Expression
Thoracic aortic ET A Rc protein expression was increased by CsA treatment compared with control (Pϭ0.004) (Fig. 4) . CsA-exposed animals that received BH 4 therapy had ET A Rc expression that was similar to control. ET B Rc protein expression was not significantly different between control and CsA-treated animals. However, BH 4 treatment (with or without CsA exposure) resulted in significant increases in ET B Rc expression compared with both control and CsA (Pϭ0.02).
Nitric Oxide Synthase Expression
eNOS protein expression was lower in CsA-treated animals compared with control (PϽ0.01) (Fig. 5) . Although BH 4 therapy attenuated the CsA-induced reduction in eNOS protein expression, it did not normalize it to control levels. However, iNOS expression was not induced in any of the experimental groups.
Oxidative Injury
CsA treatment resulted in greater oxidative injury as measured by changes in 8-isoprostane levels compared with control (CsA, 150Ϯ6% vs. control, 107Ϯ4%, Pϭ0.05). BH 4 -treated animals had similar oxidative injury as controls (BH 4 ϩCsA, 91Ϯ1%, PϾ0.05). Oxidative injury was not likely a result of an increased inflammatory response because myocardial protein expression of both TNF-␣ and TGF-␤ were similar between groups.
DISCUSSION
Our study confirms that CsA results in endothelial dysfunction. CsA treatment significantly alters normal vascular homeostasis, as demonstrated by impaired endothelial-dependent vascular dilatation. The novel aspects of our study relate to the beneficial effects of BH 4 treatment, which stabilizes ET-1-NO homeostasis. Our investigation revealed the following observations (summarized in Table 1): 1. BH 4 exposure significantly reduced plasma ET-1 levels.
2. CsA exposure significantly increased ET A Rc expression. Concomitant exposure to BH 4 attenuated the increase in ET A Rc expression.
3. BH 4 exposure (with or without concomitant CsA exposure) significantly increased ET B Rc expression.
4. CsA impaired eNOS protein expression, which was partially reversed by concomitant BH 4 therapy.
5. CsA exposure led to greater oxidative injury as measured by 8-isoprostane levels. Concomitant therapy with BH 4 attenuated superoxide production and led to similar 8-isoprostane levels as control.
6. Neither CsA nor BH 4 had any effect on cytokine production as measured by tissue levels of TNF-␣ and TGF-␤.
Normal vessel function is maintained by the balance between NO and ET-1. Our study demonstrated that CsA alters both NO and ET-1 regulation. eNOS protein expression was reduced after treatment with CsA. The reduction in eNOS protein expression may be a consequence of CsA inhibiting cyclophillin cis-trans peptidyl-prolyl isomerase function, resulting in impaired eNOS folding and therefore FIGURE 2. Cumulative dose-response curves to endothelin (ET)-1 in aortic segments. All three treatment groups demonstrated increased vasosensitivity to ET-1 compared with control. However, no significant differences were seen among CsA, BH 4 ϩCsA, and BH 4 exposed rats. increased degradation. Second, although ET-1 levels were not elevated by CsA treatment, ET A Rc protein expression in the thoracic aorta was significantly increased with no concomitant change in ET B Rc protein expression. ET A Rc and ET B Rc activation on smooth-muscle cells results in vasoconstriction, whereas ET B Rc on endothelial cells results in vasodilation. Therefore, an increased ET A Rc-to-ET B Rc ratio results in greater vasoconstriction. This was confirmed by our observation that CsA results in greater sensitivity to ET-1-induced vasospasm. CsA resulted in higher SNP ED 50 compared with the other treatment groups, indicating smooth-muscle dysfunction. Studies have suggested that CsA treatment increases free radical production, and our study confirmed that oxidative injury occurred after CsA exposure. Previous studies in our laboratory using isolated endothelial cell cultures demonstrated that CsA exposure greatly increases superoxide production (unpublished data). Therefore, oxidative injury may account for the smooth-muscle dysfunction observed in our vascular assessments. BH 4 therapy prevented the decrease in eNOS protein expression after CsA treatment. As a result, there was no impairment in endothelial-independent or dependent vasodilation. Furthermore, treatment with BH 4 therapy alone did not affect endothelial vasodilation, as demonstrated by others investigators (36, 37) . However, BH 4 treatment did result in increased sensitivity to ET-1 despite a decrease in the ET A : ET B Rc ratio, likely as a result of greater increased ET B Rc expression on smooth-muscle cells versus endothelial cells. In addition, BH 4 treatment resulted in less oxidative injury. The ability of BH 4 to reduce oxygen-derived free radical injury has been demonstrated in other models (41, 42) . Therefore, BH 4 may improve endothelial and smooth-muscle function by enhancing NO bioavailability and reducing oxidative injury.
Our findings that BH 4 improves endothelial function are consistent with studies from several other institutions (43) (44) (45) . Malo et al. (43) demonstrated that treatment with 6-methyltetrahydrobiopterin, a BH 4 analogue, limited endothelial dysfunction seen with LV hypertrophy as a result of aortic banding. They suggest that endothelial function is preserved by way of the antioxidant properties of BH 4 (43 (45) demonstrated that a glucose challenge results in impaired endothelial dependent vasodilation, which can also be prevented by BH 4 infusion. Their study was performed in healthy subjects, demonstrating the ability of BH 4 to limit endothelial dysfunction after an acute insult on previously healthy subjects (45) . This finding has implications for the prevention of endothelial injury in donor-cardiac allografts.
We therefore speculate that CsA treatment results in functional uncoupling of the eNOS enzyme, producing free radicals instead of NO and that BH 4 stabilizes the eNOS complex. As a result of this stabilization, BH 4 therapy confers protection against endothelial injury, likely by limiting superoxide production and oxidative injury.
In summary, we have made the following observations: 1. CsA results in alteration of both NO and ET-1 regulation, leading to impairment of vasodilation, increased sensitivity to vasospasm, and increased oxidative injury.
2. BH 4 can stabilize the eNOS complex and attenuate the deleterious effects on CsA.
3. BH 4 therapy may be associated with increased sensitivity to ET-1.
Our findings suggest possible treatment strategies for improving vasomotor function in patients receiving standard CsA immunosuppression. An effective strategy must include ET-1 antagonism in addition to functional coupling of eNOS. This may be achieved by using an endothelin antagonist (such as Bosentan) and BH 4 for stabilizing the eNOS complex. The results of our investigations suggest potential mechanisms for the development of CsA-induced endothelial injury, which may partially explain the common side effect of hypertension. Future studies are required to determine whether chronic BH 4 therapy with or without endothelin antagonism can prevent the development of cardiac-allograft vasculopathy. ET-1, endothelin-1; Ach, acetylcholine; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; ET-1Rc, ET-1 receptor (either A or B); Cmax%, percent maximum contraction; Emax%, phenylephrineinduced vasoconstriction.
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